Moderna: study on RSV vaccine candidate

(CercleFinance.com) - Moderna: study on RSV vaccine candidateModerna today announces that it has begun a Phase 2/3 study of mRNA-1345, its vaccine candidate developed to combat respiratory syncytial virus (RSV), a disease that generally causes cold-like symptoms.


While most people recover in about one to two weeks, RSV can be serious, especially in young children under five years of age and people of over 65, the company said.

This international Phase 2/3 study is an important milestone as we continue to advance mRNA vaccines against respiratory viruses, Moderna said.

The company plans to explore different vaccine combinations, including RSV, influenza and COVID-19.


Copyright (c) 2021 CercleFinance.com. All rights reserved.